Took some of my long positions off the table here. Want to realize some gains in case something dumb happens. What a run so far!

I been busy, I haven't sold anything! I just looked today, wow!! lets go!!!

Good call Kiwi. Going to lock in some profits.

gaining steam here!!

The only good thing is Ardelyx Assist gets patients Xphozah for $0, which is a blessing for those people in need. But it also translates to $0 for shareholders lol.

Wow, sorry longs.

They have $58M left...

That was a terrible Q1!! negative quarter over quarter. Not good...

RS to get ready to start diluting shareholders again....? Curious to see how much cash they have left on next ER.

All you can do here is average down if you have funds. Brighter days ahead of us 🌞

Still diluting and taking investor money, no end in sight. In 2025 they added another 6,000,000 shares. 6,000,000!!! in 3 months...

https://www.financecharts.com/stocks/RIOT/income-statement/shares-outstanding
12/31/2024 344.89M 49.41%
9/30/2024 324.28M 65.20%
6/30/2024 283.675M 55.61%
3/31/2024 267.992M 60.47%
12/31/2023 230.837M 37.57%
9/30/2023 196.3M 17.33%
6/30/2023 182.3M 23.18%
3/31/2023 167M 42.37%
12/31/2022 167.8M 43.79%
9/30/2022 167.3M 72.12%
6/30/2022 148M 54.33%
3/31/2022 117.3M 39.48%
12/31/2021 116.7M 48.66%
9/30/2021 97.2M 98.77%
6/30/2021 95.9M 162.02%
3/31/2021 84.1M 171.29%
12/31/2020 78.5M 212.75%
9/30/2020 48.9M 102.07%
6/30/2020 36.6M 61.95%
3/31/2020 31M 109.46%

Cheers to depression?? 😂. Looking at the chart it's telling me to accumulate. And if your are right...we can cheers to double digits!
Still adding to position. Getting better at catching these🔪👏
Best of luck to you sir!

That's when I'll be buying more lol.

We are in the anger stage...
https://investorshub.advfn.com/uimage/uploads/2025/3/31/qyxskPsychology_of_a_Market_Cycle.jpg

I bought 1 share of this on 2/1/2022 to keep track of it in my portfolio. It was $3.45 and is now -99.98% 😂

I love the conviction from the longs here 👊

Lol 😂 👍️

Do they get awarded yearly stock options? It would be really shady if they are fattening up their wallets by manufacturing a decline.

From their website

What is a washout also? How long did patients stop taking previous binder?

https://ir.unicycive.com/news/detail/73/unicycive-therapeutics-achieves-study-objective-in

While the study was not designed to evaluate efficacy, the trial enrolled patients on stable doses of approved hyperphosphatemia medications. At baseline approximately 59% of patients had phosphate levels =5.5 mg/dL, the level recommended by KDOQI guidelines. After washout from the prior phosphate binders, 90% of patients were able to achieve phosphate levels =5.5ng/dL at the end of titration with OLC.

lol at home free…common guys. We are in ARDX, did you guys see what Xphozah went through. Their initial PDUFA was in July 2021, FDA rejected it because they said the data was unclear (even though it was). They did an additional trial and resubmitted data and FDA rejected it again. The crazy part is they did exactly what FDA asked for, the data was good, but they still rejected it. That was unbelievable. They had to file an appeal and the Adcom was scheduled for October 2022. In the Adcom big pharma planted reps in that meeting to go against them. They ended up getting a 9-4 approval recommendation. Then after recommended label changes it was finally approved in October 2023.

That’s why I think OLC PDUFA is going to be rejected. They did not have specific trials for efficacy. The FDA is in the pockets of big pharma and OLC will disrupt that revenue stream. There going to have FDA press for more data exactly like they did to X. it’s going to be a long fight for UNCY.

I honestly think my investment here is going to go close to zero. But hey, you never know. Maybe the FDA gods will be forgiving. And while you guys celebrate with your boat load of shares I’ll cheer you on from my rubber raft of shares. Good luck guys

I think they need to be prepared and take care of business prior to the PDUFA. If they RS before it will give them time to come compliant and run an ATM to raise funds to keep company going regardless of outcome. The company needs a longer runway. Management needs to be smart. I would vote in favor. It would be a strike out or home run investment.

Also an RS prior and get granted FDA approval, talk about an explosion on a small float. Shorts will get absolutely buried.

IMO It should be extended for the life of patent until generics are available.

The patient should have access to whatever drug works best for them. Whether it’s a binder or blocker. The government is over stepping their boundaries from political lobbying in favor of companies to profit. Rather than letting professional rheumatologists and nephrologist do what’s best.

In my opinion: If you are running a company you concentrate on the operations, manufacturing, sales, and pipeline. The things you can control. They don't sit in a room talking about share price which is completely out of their control. I don't think they care what the share price is at, even if its underwater. They're longer than anyone..

As for me, I just got here. So my DD is really basic. I see stock that has taken a beating for 1 year. The revenue now matches what I believe is fair value for the market cap. They have an extensive pipeline, which R&D is very costly. But they have a fair amount of cash on hand to sustain for the rest of the year. With potential of revenue increasing, but this is not guaranteed. From what other longs have said, management is not the greatest. So transparency and what they say will not always be what they do.

Building a position here now has less down side risk. I would say at most the market cap can decrease by another 30% from bad news, which would put market cap at $0.85 Billion or the SP would be at about $2.65. This would not last long, maybe wick down and V shaped recovery. It would be complete flush of retail.
But it's impossible to always buy the bottom and sell the top. It just appears to me that now is the time to accumulate as the potential of the upside is 50% or much much higher with patience. And when I say patience, it could be years.

Good luck

GMH / Badger, Thanks for replies and info 🤙

How is this good?

Once TDAPA ends and the drug is incorporated into the bundle without a rate adjustment, facilities may have financial incentives to limit use of costlier new drugs

Revenue will also send this higher. Q1 numbers in May will be important.

I think they need to do a RS soon. Super important to stay listed on big board to secure financing.

Did the OS just jump 20M shares? Was that from an ATM previously.

I got a small position. I want to see what FDA says. They fought so hard to reject ARDX's Xphozah. I want to see if the same is going to happen here...

This played out exactly. Added after hours and will continue building my position. I put in multiple orders increasing in size down to the all time low. I think this is the last leg down, and will consolidate and chop sideways. Going to scale out of position at any bump up to $6 and up. That’s my plan. Good luck guys

Sorry longs... 🫠 I feel your pain

I can't do those other ones. Just bitcoins for me and some IBIT.

Did you buy this dip or just holding?

Nice little correction. My last profit taking was around $98K. Anyone buying? I haven't bought since that dip to $49k, I had a bunch orders on the way down and they all went through. That was about 8 months ago.

I'll buy some shares tomorrow so I have skin in the game....

Doing some DD. It looks like they're missing phases. There was no phase II and III that I could find on OLC. Usually phase I is only for safety and tolerability. They skipped and went straight to a pivotal clinical trial. I think FDA is going to ask for more efficacy data and another trial.

The way they put ARDX's Xphozah through the ringer with all the trials that proved it worked. It got rejected twice and had to go to adcom. 2023: Advisory committee meeting to review the drug's data. After an eight-hour deliberation, the FDA’s Cardiovascular and Renal Drug Advisory Committee voted 9-4 in favor of the med.

This is big pharma influence on FDA, until data proves that it can no longer be rejected. So UNCY is going to have to fight. I think they are years out to be honest. But that's just my opinion based on what happened with X.

https://ir.unicycive.com/news

https://ir.unicycive.com/news/detail/73/unicycive-therapeutics-achieves-study-objective-in
Out of one of the paragraphs in IR article above:
While the study was not designed to evaluate efficacy, the trial enrolled patients on stable doses of approved hyperphosphatemia medications. At baseline approximately 59% of patients had phosphate levels ≤5.5 mg/dL, the level recommended by KDOQI guidelines. After washout from the prior phosphate binders, 90% of patients were able to achieve phosphate levels ≤5.5ng/dL at the end of titration with OLC.

I think you're right which is why Ibsrela had a great Q4. Off label prescription